Standout Papers

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Dia... 1998 2026 2007 2016 5.3k
  1. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (2001)
    Barry M. Brenner, Mark E. Cooper et al. New England Journal of Medicine
  2. Organoid Models and Applications in Biomedical Research (2015)
    Christodoulos Xinaris, Valerio Brizi et al. ˜The œNephron journals/Nephron journals
  3. COVID-19 and Italy: what next? (2020)
    Andrea Remuzzi, Giuseppe Remuzzi The Lancet
  4. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease (2009)
    Marc A. Pfeffer, Emmanuel A. Burdmann et al. New England Journal of Medicine
  5. von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome (1998)
    Miha Furlan, Rodolfo Robles et al. New England Journal of Medicine
  6. Pathophysiology of Progressive Nephropathies (1998)
    Giuseppe Remuzzi, Tullio Bertani New England Journal of Medicine
  7. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases (2011)
    William G. Couser, Giuseppe Remuzzi et al. Kidney International
  8. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis (2016)
    Pietro Amedeo Modesti, Gianpaolo Reboldi et al. PLoS ONE
  9. Atypical Hemolytic–Uremic Syndrome (2009)
    Marina Noris, Giuseppe Remuzzi New England Journal of Medicine
  10. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease (2013)
    Dick de Zeeuw, Tadao Akizawa et al. New England Journal of Medicine
  11. Delayed graft function in kidney transplantation (2004)
    Norberto Perico, Dario Cattaneo et al. The Lancet
  12. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL (2004)
    Dick de Zeeuw, Giuseppe Remuzzi et al. Kidney International
  13. Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype (2010)
    Marina Noris, Jessica Caprioli et al. Clinical Journal of the American Society of Nephrology
  14. Preventing Microalbuminuria in Type 2 Diabetes (2004)
    Piero Ruggenenti, Anna Fassi et al. New England Journal of Medicine
  15. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria (1999)
    Piero Ruggenenti, Annalisa Perna et al. The Lancet
  16. Chronic kidney disease (2017)
    Paola Romagnani, Giuseppe Remuzzi et al. Nature Reviews Disease Primers
  17. Overview of Complement Activation and Regulation (2013)
    Marina Noris, Giuseppe Remuzzi Seminars in Nephrology
  18. Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure (2004)
    Marina Morigi, Barbara Imberti et al. Journal of the American Society of Nephrology
  19. How Does Proteinuria Cause Progressive Renal Damage? (2006)
    Mauro Abbate, Carla Zoja et al. Journal of the American Society of Nephrology
  20. Angiotensin II revisited: new roles in inflammation, immunology and aging (2010)
    Ariela Benigni, Paola Cassis et al. EMBO Molecular Medicine
  21. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004)
    Dick de Zeeuw, Giuseppe Remuzzi et al. Circulation
  22. Understanding the nature of renal disease progression (1997)
    Giuseppe Remuzzi, Piero Ruggenenti et al. Kidney International
  23. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome (2006)
    Jessica Caprioli, Marina Noris et al. Blood
  24. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial (2010)
    Dick de Zeeuw, Rajiv Agarwal et al. The Lancet
  25. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy (2015)
    George L. Bakris, Rajiv Agarwal et al. JAMA
  26. Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia (1983)
    Pier Mannuccio Mannucci, Giuseppe Remuzzi et al. New England Journal of Medicine
  27. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 (2020)
    Luca Perico, Ariela Benigni et al. Nature Reviews Nephrology
  28. Podocytopathies (2020)
    Jeffrey B. Kopp, Hans‐Joachim Anders et al. Nature Reviews Disease Primers
  29. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study (2016)
    Ravindra L. Mehta, Emmanuel A. Burdmann et al. The Lancet
  30. Glomerular hyperfiltration (2022)
    Monica Cortinovis, Norberto Perico et al. Nature Reviews Nephrology

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 83 standout
Sub-graph 1 of 19

Citing Papers

The immunology and immunopathology of COVID-19
2022 StandoutScience
Empagliflozin in Patients with Chronic Kidney Disease
2022 Standout
31 intermediate papers

Works of Giuseppe Remuzzi being referenced

ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
2017
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
2001 Standout
and 45 more

Author Peers

Author Last Decade Papers Cites
Giuseppe Remuzzi 36624 17561 17583 1.3k 92.7k
Jean‐Louis Vincent 14426 12087 16697 1.4k 136.1k
Josef Coresh 49539 2507 29995 936 112.1k
Andrew S. Levey 64184 2395 30240 503 121.9k
Rinaldo Bellomo 37319 4485 12341 1.6k 96.4k
Tom Greene 38211 1514 17550 475 79.0k
John J.V. McMurray 8102 3179 84097 1.5k 126.4k
Russell P. Tracy 4227 7452 22740 663 85.4k
Paul M. Ridker 3253 20587 37641 811 127.8k
Dirk J. van Veldhuisen 5517 2958 42486 852 58.8k
Glenn M. Chertow 41469 1025 11265 800 67.2k

All Works

Loading papers...

Rankless by CCL
2026